Whittier Trust Co. of Nevada Inc. Purchases 1,925 Shares of Axon Enterprise, Inc. (NASDAQ:AXON)

Whittier Trust Co. of Nevada Inc. raised its position in shares of Axon Enterprise, Inc. (NASDAQ:AXON) by 23.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,215 shares of the biotechnology company’s stock after acquiring an additional 1,925 shares during the period. Whittier Trust Co. of Nevada Inc.’s holdings in Axon Enterprise were worth $6,071,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the company. Geode Capital Management LLC boosted its holdings in Axon Enterprise by 2.0% during the third quarter. Geode Capital Management LLC now owns 1,782,828 shares of the biotechnology company’s stock valued at $710,103,000 after acquiring an additional 35,320 shares during the period. Westfield Capital Management Co. LP boosted its holdings in Axon Enterprise by 12.2% during the third quarter. Westfield Capital Management Co. LP now owns 1,175,328 shares of the biotechnology company’s stock valued at $469,661,000 after acquiring an additional 127,769 shares during the period. Champlain Investment Partners LLC boosted its holdings in Axon Enterprise by 13.9% during the third quarter. Champlain Investment Partners LLC now owns 682,420 shares of the biotechnology company’s stock valued at $272,695,000 after acquiring an additional 83,265 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Axon Enterprise by 1.6% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 561,263 shares of the biotechnology company’s stock valued at $224,281,000 after acquiring an additional 9,090 shares during the period. Finally, Groupama Asset Managment bought a new stake in Axon Enterprise during the third quarter valued at about $200,000. 79.08% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Axon Enterprise news, Director Caitlin Elizabeth Kalinowski sold 450 shares of the company’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $604.07, for a total transaction of $271,831.50. Following the sale, the director now directly owns 6,929 shares of the company’s stock, valued at approximately $4,185,601.03. This represents a 6.10 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jeri Williams sold 307 shares of the company’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $552.72, for a total transaction of $169,685.04. Following the sale, the director now directly owns 1,627 shares in the company, valued at $899,275.44. This represents a 15.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 1,792 shares of company stock valued at $1,087,843. 5.70% of the stock is currently owned by insiders.

Axon Enterprise Stock Performance

NASDAQ:AXON opened at $560.00 on Friday. Axon Enterprise, Inc. has a 12-month low of $273.52 and a 12-month high of $715.99. The company has a quick ratio of 2.63, a current ratio of 2.96 and a debt-to-equity ratio of 0.32. The firm has a market capitalization of $42.91 billion, a PE ratio of 144.70, a price-to-earnings-growth ratio of 5.17 and a beta of 1.12. The firm has a 50-day moving average price of $591.90 and a 200 day moving average price of $540.96.

Analyst Ratings Changes

A number of brokerages have recently commented on AXON. JMP Securities reaffirmed an “outperform” rating on shares of Axon Enterprise in a research report on Tuesday, February 4th. Northcoast Research lowered shares of Axon Enterprise from a “buy” rating to a “neutral” rating in a research report on Wednesday, February 19th. Morgan Stanley raised shares of Axon Enterprise from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $500.00 to $700.00 in a research report on Tuesday, December 3rd. Barclays reaffirmed a “hold” rating on shares of Axon Enterprise in a research report on Monday, March 10th. Finally, The Goldman Sachs Group upped their price objective on shares of Axon Enterprise from $500.00 to $700.00 and gave the company a “buy” rating in a research report on Monday, January 27th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $604.67.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.